Silverback Therapeutics, Inc. (SBTX) |
|
5.87 0.06 (1.03%)
|
11-09 00:00 |
|
Open: |
5.82 |
Pre. Close: |
5.81 |
|
High:
|
6.15 |
Low:
|
5.82 |
|
Volume:
|
116,690 |
Market Cap:
|
550(M) |
|
|
|
Technical analysis |
as of: 2022-11-18 4:24:33 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 7.58 One year: 8.85 |
| Support: |
Support1: 5.59  Support2: 5.03 |
| Resistance: |
Resistance1: 6.48 Resistance2: 7.58 |
| Pivot: |
5.97 |
| Moving Average: |
MA(5): 5.86 MA(20): 5.95 
MA(100): 5.17 MA(250): 4.7 |
| MACD: |
MACD(12,26): 0 Signal(9): 0.1 |
| Stochastic oscillator: |
%K(14,3): 32.2 %D(3): 33.9 |
| RSI: |
RSI(14): 53.5 |
| 52-week: |
High: 7.54 Low: 2.79 |
| Average Vol(K): |
3-Month: 166 (K) 10-Days: 122 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SBTX ] has closed above bottom band by 32.2%. Bollinger Bands are 37.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
6.16 - 6.19 |
6.19 - 6.22 |
|
Low:
|
5.74 - 5.78 |
5.78 - 5.81 |
|
Close:
|
5.81 - 5.87 |
5.87 - 5.92 |
|
Company Description |
|
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. |
Headline News |
Sun, 20 Nov 2022
ARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake ... - Nasdaq
Fri, 21 Oct 2022
Silverback Therapeutics, Inc. announces the FDA's acceptance of ... - Business Wire
Mon, 25 Jul 2022
Silverback Therapeutics plans merger with San Diego biotech - The Business Journals
Thu, 21 Jul 2022
Silverback Therapeutics and ARS Pharmaceuticals Announce Merger - Business Wire
Fri, 08 Apr 2022
Silverback Therapeutics Inc. - Investing News Network
Thu, 31 Mar 2022
Silverback Therapeutics Updates Strategic Priorities and Reports ... - Business Wire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
35 (M) |
| Shares Float |
22 (M) |
|
% Held by Insiders
|
1.6 (%) |
|
% Held by Institutions
|
80.1 (%) |
|
Shares Short
|
898 (K) |
|
Shares Short P.Month
|
543 (K) |
Stock Financials |
|
EPS
|
-2.74 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
7.92 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-17.2 |
|
Return on Equity (ttm)
|
-28.8 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-2.54 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-75 (M) |
|
Levered Free Cash Flow
|
-43 (M) |
Stock Valuations |
|
PE Ratio
|
-2.16 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.74 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-2.77 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
